CLINICAL TRIALS PROFILE FOR OLUMIANT

All Clinical Trials for OLUMIANT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03921554 ↗	JAK Inhibitor Treatment in AGS	Active, not recruiting	Eli Lilly and Company	Phase 2	2019-06-03	The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
NCT03921554 ↗	JAK Inhibitor Treatment in AGS	Active, not recruiting	Adeline Vanderver, MD	Phase 2	2019-06-03	The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
NCT04131738 ↗	Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation	Recruiting	Washington University School of Medicine	Phase 1	2020-04-07	In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2 inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease (aGVHD).
NCT04345289 ↗	Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia	Not yet recruiting	Thomas Benfield	Phase 3	2020-04-20	CCAP is an investigator-initiated multicentre, randomized, double blinded, placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel treatment option of moderate-severe COVID-19. Participants will be randomized 1:1:1:1:1:1 to parallel treatment arms: Convalescent plasma, sarilumab, hydroxychloroquine, baricitinib, intravenous and subcutaneous placebo, or oral placebo. Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days.
NCT04390464 ↗	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)	Recruiting	Cambridge University Hospitals NHS Foundation Trust	Phase 4	2020-05-08	TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID19 appears to be due to a later, exaggerated, host immune response. This leads to lung and sometimes multi-organ damage. Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. Therefore, this study proposes to assess the efficacy of immunomodulatory agents that target dysregulated immune response that drive the severe lung, and other organ, damage. The medications investigated for efficacy in this trial are Baricitinib and Ravulizumab.
NCT04399798 ↗	Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial	Not yet recruiting	IRCCS Policlinico S. Matteo	Phase 2	2020-05-15	The objective of the study is to assess the efficacy and safety of Baricitinib in the treatment of patients with COVID-19 pneumonia. This will be a proof-of-concept trial with an exploratory single-arm proof of concept Phase IIa study to assess the efficacy and safety profile of Baricitinib in a limited number of patients with severe acute respiratory syndrome (SARS)-CoV-2 pneumonia. If the initial proof of concept phase will lead to favourable results, an open-label, Phase II, randomized controlled trial will be then designed and performed to confirm the results obtained in the proof of concept phase. The proof-of-concept phase guarantees that no safety issues arise on a limited number of patients in the use of a drug new to the current condition being treated.
NCT04832880 ↗	Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)	Not yet recruiting	ASST Fatebenefratelli Sacco	Phase 3	2021-04-06	Background: In the current worldwide medical emergency, a rapid identification of effective therapeutic strategy is crucial. So far, therapy with dexamethasone, remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19, but the effect of baricitinib and remdesivir in combination with dexamethasone. The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency (AIFA-Agenzia Italiana del Farmaco)

Clinical Trial Conditions for OLUMIANT

Condition Name

Condition Name for OLUMIANT
Intervention	Trials
Corona Virus Infection	2
Covid19	2
Pyoderma Gangrenosum	1
Aicardi Goutieres Syndrome	1

Condition MeSH

Condition MeSH for OLUMIANT
Intervention	Trials
COVID-19	3
Pneumonia	2
Coronavirus Infections	2
Sclerosis	2

Clinical Trial Locations for OLUMIANT

Trials by Country

Trials by Country for OLUMIANT
Location	Trials
United States	12
China	4
Italy	2
Luxembourg	1
Slovakia	1

Trials by US State

Trials by US State for OLUMIANT
Location	Trials
North Carolina	1
Tennessee	1
Minnesota	1
Georgia	1
Connecticut	1

Clinical Trial Progress for OLUMIANT

Clinical Trial Phase

Clinical Trial Phase for OLUMIANT
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for OLUMIANT
Clinical Trial Phase	Trials
Not yet recruiting	7
Recruiting	7
Active, not recruiting	1

Clinical Trial Sponsors for OLUMIANT

Sponsor Name

Sponsor Name for OLUMIANT
Sponsor	Trials
Eli Lilly and Company	2
Holy Cross Hospital, Florida	1
Navy General Hospital, Beijing	1

Sponsor Type

Sponsor Type for OLUMIANT
Sponsor	Trials
Other	32
Industry	4

Olumiant (baricitinib): Clinical-trials update, market analysis, and projection

Last updated: April 28, 2026

What is the current clinical-trials position for Olumiant (baricitinib)?

Olumiant is an oral JAK inhibitor approved in multiple indications and studied across inflammatory and immune-mediated diseases. The most commercially material late-stage clinical program in recent years remains the rheumatoid arthritis (RA) line, with ongoing expansion into earlier disease settings and combination strategies in several regions. Across indications, the development pattern is consistent: new studies aim to (1) expand label breadth (new disease subtypes or earlier intervention windows) and (2) defend efficacy and safety positioning versus other JAK inhibitors and biologics through head-to-head or standardized background-therapy trials.

Commercially relevant indication clusters where active studies have historically concentrated

• Rheumatoid arthritis (RA): clinical work centers on durability, dose optimization, combination regimens, and comparisons to standard-of-care biologics and methotrexate-based strategies (multiple trial phases in major geographies across recent years).
• Atopic dermatitis (AD): studies typically address itch and skin clearance endpoints, stratification by severity and treatment history, and long-term safety continuation.
• Alopecia areata (AA): development has focused on scalp hair regrowth durability and safety in longer treatment horizons.
• COVID-19: late-stage and post-authorization use has largely shifted from new pivotal enrollment toward real-world evidence and regimen-specific evaluation (timing, setting, and steroid background are the typical differentiators).
• Other immune-mediated indications (e.g., psoriatic arthritis, uveitis variants, interstitial lung disease subsets, and inflammatory bowel disease subsets): programs typically run as signal-expansion or biomarker-linked cohorts.

How to read the clinical-trials update for decision-making

• If the objective is label expansion, watch for trials that change the care position (earlier lines, broader patient eligibility, or switching from biologics to oral therapy).
• If the objective is defense, focus on trials that maintain comparable endpoints against other JAK inhibitors, especially safety-relevant endpoints tied to cardiovascular and thromboembolic risk frameworks used by regulators.

Status anchor: Olumiant’s approvals and core evidence base are already established in RA, and the development effort has been moving toward label durability and broader inflammatory disease coverage. [1], [2]

How has the approved-market structure evolved?

Olumiant’s market is segmented by (1) indication, (2) line of therapy, (3) geography, and (4) patient selection framed by safety, comorbidity, and prior biologic exposure.

Key approved indications that drive revenue allocation

• Rheumatoid arthritis (RA): adult patients with moderate to severe disease who have had inadequate response or intolerance to one or more TNF inhibitors in earlier eras of development; subsequent label refinements broaden usage pathways depending on region and timeline. [1], [2]
• Other inflammatory indications with active commercial contribution historically include atopic dermatitis, alopecia areata, and COVID-19 (where commercial relevance depends on the persistence of payer and guideline recommendations by variant and clinical setting). [1], [2]

Where does Olumiant compete in the current JAK landscape?

Olumiant competes primarily inside the oral JAK inhibitor category and secondarily versus biologics.

Competitive set (commercially relevant)

• Within JAKs: tofacitinib, upadacitinib, filgotinib (where approved/available), and other JAK inhibitors depending on geography and label overlap.
• Versus biologics: TNF inhibitors and IL-6/IL-17/IL-23 class agents in dermatology and rheumatology, and TNF or integrin pathway agents in certain inflammatory settings.

Competitive strategy implications

• JAKs compete on route of administration (oral), speed of symptom relief, and switch feasibility after inadequate response to prior biologics.
• Payer control typically hinges on step therapy, prior authorization, and evidence of inadequate response.

What is the current market sizing and growth direction for Olumiant?

A full, audit-grade market model requires payer pricing, unit volume by geography, and treatment mix by line of therapy. Those inputs are not provided here. What is provided is a reliable directional market view based on the role of baricitinib in the JAK class, its label footprint, and the competitive structure.

Market direction (high-level)

• RA remains the core revenue anchor because it is the largest durable autoimmune franchise within baricitinib’s label set and supports repeat prescriptions through long-term therapy. [1], [2]
• Dermatology indications are margin and volume drivers where approved populations are large and treatment switching from injectables to oral agents can occur. [1], [2]
• COVID-19 commercial value is episodic and depends on the standard-of-care regimen, steroid background, and the extent to which payer guidance continues to fund a JAK inhibitor pathway for specific patient subsets. [1], [2]

Implication for investment and R&D

• If the company can extend label breadth or reduce restriction barriers (earlier line, broader eligibility, less stringent prior biologic history), it typically increases the addressable pool faster than incremental safety refinements alone.
• If other JAKs win formulary preference in a key geography, the market share headwind appears even when the overall class grows.

What demand drivers and risks matter most to projections?

Demand drivers

• Oral convenience and switching behavior: patients and prescribers favor oral therapies when efficacy and safety profiles align with guideline thresholds.
• Broader label access: any expansion that reduces unmet-need filtering (prior biologic constraints) expands the eligible pool. [1], [2]
• Long-term durability in RA and select dermatology indications, which supports recurring prescription dynamics.

Key risks

• Class competition and formulary dynamics: other JAK inhibitors often compete with aggressive pricing or strong payer evidence packages.
• Safety-related reimbursement friction: regulators and payers apply risk frameworks that can alter who qualifies for therapy.
• Guideline and standard-of-care drift: especially in COVID-19, where clinical practice depends on variant severity patterns and co-therapies.

How should Olumiant market projections be framed for business planning?

Without proprietary pricing and volume inputs, projections should be structured as scenario bands tied to measurable levers: label breadth, formulary access, competitor share gains/losses, and indication-level penetration.

Scenario framework (projection method)

1. Base case: RA and dermatology remain steady-to-moderate growth; COVID-19 remains non-core and fluctuates with clinical practice. [1], [2]
2. Upside case: demonstrable label expansions or reduced reimbursement barriers in high-volume segments; higher persistence due to improved patient adherence and tolerability.
3. Downside case: faster share loss to newer JAKs or biologics in competitive geographies; increased restriction criteria for safety-relevant subgroups.

What to track monthly for real-time validation

• Tender and formulary updates in top markets (US, EU5, Japan, and major emerging markets).
• Prescription persistence trends in RA (discontinuation and switch rates).
• Dermatology patient growth tied to dermatology guideline uptake and payer coverage expansions.
• Competitor launch sequencing and evidence-driven reimbursement changes.

What is the likely near-to-mid-term outlook (12 to 36 months)?

• RA: continues to drive the majority of revenue contribution; growth depends on persistence, modest uptake in additional patient subsets, and maintaining share against other oral and biologic options. [1], [2]
• Dermatology: should remain a key growth vector, with penetration dependent on payer coverage stability and dermatologist adoption of JAK inhibitor class guidance. [1], [2]
• COVID-19: expected to remain lower priority commercially relative to chronic indications, with volatility driven by practice patterns. [1], [2]

---

Key Takeaways

• Olumiant’s commercial engine is chronic immune disease exposure, led by RA, with dermatology indications supporting incremental growth. [1], [2]
• Clinical development emphasis is label breadth, durability, and combination or eligibility refinement, which determines incremental addressable patient pools.
• Projections should be scenario-based, anchored on formulary and payer restrictions, and validated against prescription persistence in RA and uptake in dermatology.
• The competitive risk is share shift within the JAK class, where reimbursement and risk framing often decide winners in line-of-therapy contests.

---

FAQs

1) What is Olumiant’s primary revenue driver?

Rheumatoid arthritis is the core durable franchise that supports long-term prescriptions and revenue stability. [1], [2]

2) Which indications matter most beyond RA?

Atopic dermatitis and alopecia areata are the most commercially relevant beyond RA in the baricitinib label footprint. [1], [2]

3) Is COVID-19 still a major part of Olumiant’s market?

COVID-19 is more volatile and less structurally dependable than chronic indications, with commercial value tied to evolving standard of care and patient selection. [1], [2]

4) How do formulary decisions typically affect Olumiant’s growth?

Formulary access and prior-authorization criteria largely determine who can be treated and at what line of therapy, which directly impacts unit growth.

5) What clinical-trial outcomes would most move the market outlook?

Trials that expand earlier-line eligibility, reduce payer restriction criteria, or demonstrate durable efficacy and acceptable safety in broader subgroups tend to have the highest commercial impact. [1], [2]

---

References (APA)

[1] Eli Lilly and Company. (n.d.). Olumiant (baricitinib) prescribing information and product information.
[2] European Medicines Agency. (n.d.). Olumiant (baricitinib) EPAR: information for authorised use and indications.